Publications of Tiago F. Outeiro
All genres
Journal Article (130)
101.
Journal Article
119, pp. 121 - 135 (2018)
Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function. Neurobiology of Disease 102.
Journal Article
115 (41), pp. 10481 - 10486 (2018)
Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proceedings of the National Academy of Sciences of the United States of America 103.
Journal Article
9, 97 (2017)
The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 104.
Journal Article
20 (11), pp. 1569 - 1579 (2017)
Alpha-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nature Neuroscience 105.
Journal Article
7, 13713 (2017)
Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Scientific Reports 106.
Journal Article
32 (9), pp. 1331 - 1333 (2017)
Neuromelanin magnetic resonance imaging of the Substantia Nigra in LRRK2-related Parkinson's disease. Movement Disorders 107.
Journal Article
295, pp. 77 - 87 (2017)
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. Experimental Neurology 108.
Journal Article
56, pp. 7 - 16 (2017)
Sirtuin 2 enhances dopaminergic differentiation via the AKT/GSK-3β/β-catenin pathway. Neurobiology of Aging 109.
Journal Article
73 (4), pp. 459 - 467 (2017)
IGF-I gene therapy in aging rats modulates hippocampal genes relevant to memory function. Journals of Gerontology: Series A, Biological Sciences and Medical Sciences 110.
Journal Article
26 (12), pp. 2231 - 2246 (2017)
Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. Human Molecular Genetics 111.
Journal Article
114 (25), pp. E4971 - E4977 (2017)
Treatment with diphenyl-pyrazole compound anle138b/c reveals that alpha-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America 112.
Journal Article
114 (25), pp. E4971 - E4977 (2017)
Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America 113.
Journal Article
140, pp. 1399 - 1419 (2017)
Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain 114.
Journal Article
140, pp. 878 - 886 (2017)
The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease. Brain 115.
Journal Article
15 (3), e1002601 (2017)
The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biology 116.
Journal Article
7, 42942 (2017)
Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress. Scientific Reports 117.
Journal Article
26 (19), pp. 3763 - 3775 (2017)
Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity. Human Molecular Genetics 118.
Journal Article
37, pp. 121 - 131 (2017)
Cellular uptake of α-Synuclein oligomer-selective antibodies is enhanced by the extracellular presence of α-Synuclein and mediated via Fcγ receptors. Cellular and Molecular Neurobiology 119.
Journal Article
40, pp. 168 - 181 (2017)
Cell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain. Ageing Research Reviews 120.
Journal Article
4, 128 (2016)
The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. Acta Neuropathologica Communications